US Patent 11,530,197 B2 covers the compound that became rentosertib, the TNIK inhibitor that Insilico Medicine says is the first
No AI Has Ever Been Named Inventor on a Drug Patent. Here’s the Rule That Guarantees It. Read Post »
The FDA Orange Book does not link to the USPTO’s patent database. The USPTO’s patent database does not link to
The Free Patent Database Costing Your Team Thousands an Hour in Manual Cross-Referencing Read Post »
Eliquis has four expiration dates. Not one, not two. Four. The composition-of-matter patent covering apixaban was originally set to expire
A comprehensive freedom-to-operate analysis for a pharmaceutical asset takes four to twelve weeks and costs $50,000 to $200,000 in legal
On September 9, 2026, Bristol-Myers Squibb’s five-year new chemical entity (NCE) exclusivity for Sotyktu (deucravacitinib) reaches its four-year mark. That
On October 8, 2025, the U.S. Patent and Trademark Office quietly admitted something the patent search industry had been saying
Stop Searching Patents. Start Asking Them Questions. Read Post »
The Short Answer A pharmaceutical patent lawsuit becomes public the moment it is entered on a federal docket. Nobody has
Eight of Teva’s nine Copaxone patents expired in May 2014. The first FDA-approved generic, Sandoz’s Glatopa, didn’t reach a pharmacy
The Three-Clock Problem: Why Patent Expiration Dates Don’t Predict Generic Launch Dates Read Post »
In March 2022, the first generic version of Bristol Myers Squibb’s cancer drug Revlimid reached U.S. pharmacies. It launched at
Sign in or create a free account to read this DrugPatentWatch article
